The ability of the flutamide metabolite Sch 16423 to block androgen receptor binding and inhibit masculine copulatory behavior in male rats was examined. Restoration of copulatory behavior was prevented in Sch 16423-treated rats given two 10-mm testosterone (T)-filled Silastic capsules plus 15 mg Sch 16423 daily for 11 days. Control males receiving only T-filled capsules copulated successfully. To test maintenance of copulatory behavior, T-filled capsules were implanted at the time of castration and rats received daily injections of either 0, 1, 5, 15 or 30 mg Sch 16423. Ejaculation was not prevented by Sch 16423 treatment, suggesting only a weak effect of Sch 16423 on the maintenance of copulatory behavior. An exchange assay was used to determine the effects of Sch 16423 on cell nuclear androgen receptor binding both in vivo and in vitro. For in vivo tests, castrate males bearing two 10-mm T-filled capsules received a single injection of either 0, 1, 5, or 15 mg Sch 16423 1 h prior to sacrifice. Androgen receptor binding was drastically reduced in both brain (combined hypothalamus, preoptic area, amygdala and septum) and pituitary at all doses of Sch 16423. For in vitro assays, samples from brain and pituitary were incubated with 10–10 to 10–6 M dihydrotestosterone (DHT), Sch 16423 or flutamide. Sch 16423 competed for androgen receptors in vitro, though not as effectively as DHT. Flutamide was a poor competitor. These results indicate that Sch 16423 effectively reduces masculine copulatory potential primarily affecting restoration of behavior, and that Sch 16423 inhibited cell nuclear androgen receptor binding both in vivo and in vitro. Sch 16423 may serve as a valuable tool for the exploration of androgen action in brain.

This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.